Rank/Rankl/opg: literature review
- PMID: 22113597
Rank/Rankl/opg: literature review
Abstract
The discovery of the receptor activator of nuclear factor-kB (RANK)/RANK Ligand (RANKL)/osteoprotegerin (OPG) pathway contributed to the understanding of how bone formation and resorption were processed and regulated. RANKL and OPG are members of the tumor necrosis factor (TNF) and TNF receptor (TNFr) superfamilies, respectively, and binding to receptor activator of NF-kB (RANK) not only regulate osteoclast formation, activation and survival in normal bone modeling and remode-ling, but also in several other pathologic conditions characterized by increased bone turnover. There is accumulating evidence of the potential role of OPG and RANKL in other tissues. Looking beyond the RANK/RANKL/OPG axis, Wingless (Wnt) pathway emerged as the osteoblast differentiation way, and also as a bone mass regulator. Researchers have been discovering new molecules and cytokines interactions. Altogether, data suggest that RANK/RANKL/OPG system could be targeted as a new treatment strategy in bone conditions. FREEDOM is the more recently published clinical trial about a RANKL-specific recombinant fully human monoclonal antibody (denosumab). OPG is also a potential innovative therapeutic option to be investigated.
Similar articles
-
[The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].Bull Cancer. 2011 Jul;98(7):837-46. doi: 10.1684/bdc.2011.1398. Bull Cancer. 2011. PMID: 21700551 Review. French.
-
Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.Semin Arthritis Rheum. 2010 Apr;39(5):369-83. doi: 10.1016/j.semarthrit.2008.10.008. Epub 2008 Dec 18. Semin Arthritis Rheum. 2010. PMID: 19095294 Review.
-
Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.Med Hypotheses. 2008 Aug;71(2):256-8. doi: 10.1016/j.mehy.2008.03.021. Epub 2008 Apr 28. Med Hypotheses. 2008. PMID: 18445511
-
Biology of RANK, RANKL, and osteoprotegerin.Arthritis Res Ther. 2007;9 Suppl 1(Suppl 1):S1. doi: 10.1186/ar2165. Arthritis Res Ther. 2007. PMID: 17634140 Free PMC article. Review.
-
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.J Bone Miner Res. 2001 Aug;16(8):1416-25. doi: 10.1359/jbmr.2001.16.8.1416. J Bone Miner Res. 2001. PMID: 11499864
Cited by
-
New Emerging Aspect of Herbal Extracts for the Treatment of Osteoporosis: Overview.Curr Rheumatol Rev. 2024;20(4):361-372. doi: 10.2174/0115733971273691231121131455. Curr Rheumatol Rev. 2024. PMID: 38173067 Review.
-
The clinical characteristics and prognosis of patients with SAPHO syndrome--a real-world cohort study.Clin Rheumatol. 2024 Jan;43(1):561-568. doi: 10.1007/s10067-023-06782-7. Epub 2023 Sep 27. Clin Rheumatol. 2024. PMID: 37755548
-
Lactobacillus plantarum LP45 inhibits the RANKL/OPG signaling pathway and prevents glucocorticoid-induced osteoporosis.Food Nutr Res. 2023 Mar 24;67. doi: 10.29219/fnr.v67.9064. eCollection 2023. Food Nutr Res. 2023. PMID: 37056702 Free PMC article.
-
Surgical Treatment of Peri-Implantitis Using a Combined Nd: YAG and Er: YAG Laser Approach: Investigation of Clinical and Bone Loss Biomarkers.Dent J (Basel). 2023 Feb 24;11(3):61. doi: 10.3390/dj11030061. Dent J (Basel). 2023. PMID: 36975558 Free PMC article.
-
Amyotrophic lateral sclerosis (ALS) and the endocrine system: Are there any further ties to be explored?Aging Brain. 2021 Nov 8;1:100024. doi: 10.1016/j.nbas.2021.100024. eCollection 2021. Aging Brain. 2021. PMID: 36911507 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
